<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-153260</identifier>
<setSpec>0034-947X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Etiological treatment of asthma in pre-school children</dc:title>
<dc:description xml:lang="en">Three groups of children affected by rhinitis/asthma are reviewed based on the family characteristics and amount of allergens they were sensitized to. The &amp;#64257;rst group included those between 2 and 5 years, age when basic treatment with immunotherapy was initiated. The two remaining groups included those between 5 and 8 years and 8 and 18 years, all with similar conditions whose symptoms had been manifested suf&amp;#64257;ciently before but who had only received symptomatic or anti-in&amp;#64258;ammatory treatment. A review is made of the need for early onset of immunotherapy based on their principal mechanism by which the immunological reaction is modi&amp;#64257;ed, achieving TH1/Th2 balance since the activity of the Th2 lymphocytes that promote the allergen-speci&amp;#64257;c IgE production already predominates in the atopic patients (AU)</dc:description>
<dc:creator>Muñoz-López, F</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En base a las características familiares y cantidad de alérgenos a que estaban sensibilizados, se comentan tres grupos de niños afectos de rinitis/asma, el primero de ellos de entre 2 y 5 años, edad en la que se inició tratamiento básico con inmunoterapia, y los otros dos, entre 5 y 8 años y de 8 a 18 años, todos ellos con procesos similares cuyos síntomas se habían manifestado con bastante anterioridad pero que solo habían recibido tratamiento sintomático o antiinflamatorio. Se hace una revisión de la necesidad del inicio temprano de inmunoterapia en base a su principal mecanismo por el que se modi&amp;#64257;ca la reacción inmunológica, lográndose el equilibrio Th1/Th2 ya que en los pacientes atópicos predomina la actividad de los linfocitos Th2, que promueven la producción de IgE específica frente a los alérgenos (AU)</dc:description>
<dc:source>Rev Esp Pediatr;72(1): 67-69, ene.-feb. 2016. tab</dc:source>
<dc:identifier>ibc-153260</dc:identifier>
<dc:title xml:lang="es">Tratamiento etiológico del asma en preescolares</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d27801^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d7345^s22045</dc:subject>
<dc:subject>^d2021^s22073</dc:subject>
<dc:subject>^d32005^s22038</dc:subject>
<dc:subject>^d30224^s22080</dc:subject>
<dc:subject>^d29373^s22045</dc:subject>
<dc:subject>^d54314^s22021</dc:subject>
<dc:subject>^d1257^s22067</dc:subject>
<dc:subject>^d30224^s22038</dc:subject>
<dc:subject>^d23303^s22053</dc:subject>
<dc:subject>^d1257^s22027</dc:subject>
<dc:subject>^d7345^s22074</dc:subject>
<dc:subject>^d30224^s22012</dc:subject>
<dc:subject>^d1257^s22038</dc:subject>
<dc:subject>^d27801^s22012</dc:subject>
<dc:subject>^d27801^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>201602</dc:date>
</metadata>
</record>
</ibecs-document>
